Mangoceuticals (MGRX) Net Income towards Common Stockholders (2023 - 2026)
Mangoceuticals (MGRX) posted Net Income towards Common Stockholders of -$3.7 million for Q1 2026, up 35.25% sequentially from -$5.7 million in Q4 2025, and up 27.98% YoY from -$2.9 million in Q1 2025.
Mangoceuticals (MGRX) Net Income towards Common Stockholders (2023 - 2026) Analysis & Trends
Mangoceuticals has reported Net Income towards Common Stockholders for 4 years, with the latest figure at -$3.7 million in Q1 2026.
- Quarterly Net Income towards Common Stockholders rose 27.98% year-over-year to -$3.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$22.7 million (down 93.22% YoY) and the FY2025 annual result came in at -$21.8 million, down 129.47% from the prior year.
- Net Income towards Common Stockholders advanced to -$3.7 million in Q1 2026 per MGRX's latest filing, from -$5.7 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at -$1.8 million in Q3 2023 and troughed at -$7.9 million in Q3 2025.
- A 4-year average of -$3.5 million and a median of -$2.6 million in 2023 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2025 and 2026: Net Income towards Common Stockholders plunged 245.02% in 2025, then rose 27.98% in 2026.
- Over 4 years, Net Income towards Common Stockholders stood at -$2.6 million in 2023, then advanced by 24.13% to -$1.9 million in 2024, then slumped by 193.06% to -$5.7 million in 2025, then jumped by 35.25% to -$3.7 million in 2026.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$3.7 million, -$5.7 million, and -$7.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Veeva Systems | 39.72 Bn | 32.40 Bn | 662.02 Mn | 260.94 Mn |
| 2 | BrightSpring Health Services | 12.19 Bn | 11.64 Bn | 492.75 Mn | 84.30 Mn |
| 3 | Healthequity | 8.79 Bn | 8.52 Bn | 256.31 Mn | 69.42 Mn |
| 4 | 10x Genomics | 7.31 Bn | 6.76 Bn | 112.50 Mn | -17.93 Mn |
| 5 | Hinge Health | 7.10 Bn | 6.71 Bn | 183.95 Mn | 43.10 Mn |
| 6 | MiniMed | 5.66 Bn | 5.36 Bn | 480.00 Mn | -185.00 Mn |
| 7 | Waystar Holding | 4.76 Bn | 4.56 Bn | 221.99 Mn | 40.87 Mn |
| 8 | Doximity | 4.46 Bn | 3.77 Bn | 132.93 Mn | 24.32 Mn |
| 9 | Heartflow | 3.66 Bn | 3.28 Bn | 53.19 Mn | -15.74 Mn |
| 10 | Mangoceuticals | 9.55 Mn | 9.30 Mn | 44,215.00 | -1.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.61 Mn |
| Mar 31, 2026 | -3.70 Mn |
| Dec 31, 2025 | -5.71 Mn |
| Sep 30, 2025 | -7.91 Mn |
| Jun 30, 2025 | -5.42 Mn |
| Mar 31, 2025 | -5.13 Mn |
| Dec 31, 2024 | -1.95 Mn |
| Sep 30, 2024 | -2.29 Mn |
| Jun 30, 2024 | -2.39 Mn |
| Mar 31, 2024 | -2.37 Mn |
| Dec 31, 2023 | -2.57 Mn |
| Sep 30, 2023 | -1.80 Mn |
| Jun 30, 2023 | -2.28 Mn |
| Mar 31, 2023 | -2.56 Mn |